Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.
Welcome to OncLive On Air®! I’m your host today, Ashling Wahner.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by AstraZeneca, we had the pleasure of speaking with R. Katie Kelley, MD, about the evolution of the hepatocellular carcinoma (HCC) treatment paradigm. Dr Kelley is a professor of clinical medicine in the Department of Medicine (Hematology/Oncology), as well as an affiliated faculty member in the Cancer Immunotherapy Program at the University of California San Francisco Helen Diller Family Comprehensive Cancer Center.
In our exclusive interview, Dr Kelley discussed standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial (NCT03298451), and the safety profile of the Single Tremelimumab-actl (Imjudo) Regular Interval Durvalumab (Imfinzi; STRIDE) regimen in this population.
That’s all we have for today! Thank you for listening to this episode of OncLive On Air®, sponsored by AstraZeneca. Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field.
For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive® is also on social media. On Twitter, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.